Related Experiment Videos
Fixed-dose lercanidipine/enalapril for hypertension
1Department of Nephrology, Medical School Hannover, Hannover, Germany. janmenne@gmx.de
Drugs of Today (Barcelona, Spain : 1998)
|June 10, 2008
Summary
A new fixed-dose combination of lercanidipine and enalapril offers enhanced blood pressure control for hypertensive patients. This well-tolerated combination improves compliance and may reduce treatment costs.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Internal Medicine
Background:
- Hypertension management often requires combination therapy.
- Lercanidipine (a dihydropyridine calcium channel blocker) and enalapril (an ACE inhibitor) are commonly prescribed antihypertensives.
- A fixed-dose combination addresses challenges in monotherapy non-responders.
Purpose of the Study:
- To review the literature on a new fixed-dose combination of lercanidipine and enalapril.
- To evaluate its efficacy, tolerability, and place in hypertension treatment.
- To inform healthcare providers about its availability and usage.
Main Methods:
- Literature review summarizing existing studies.
- Analysis of clinical data on efficacy and side effect profiles.
- Examination of dosing, administration, and contraindications.
Main Results:
- The fixed-dose combination (10 mg lercanidipine with 10 or 20 mg enalapril) demonstrates superior blood pressure-lowering effects compared to monotherapy.
- The combination is generally well-tolerated, with common side effects including cough and peripheral edema (1-5% incidence).
- Few patients discontinued treatment due to adverse events.
Conclusions:
- The fixed-dose combination of lercanidipine and enalapril is an effective and safe treatment option for hypertensive patients.
- It offers improved therapeutic outcomes and potentially enhanced patient compliance.
- This combination represents a valuable addition to the antihypertensive armamentarium, aiding in cost reduction.
Related Concept Videos
01:01Dosage Regimen: Fixed Dose
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:22Dose-Response Relationship: Potency and Efficacy
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...